The Jazz Board of Directors has unanimously selected Renee Gala as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. This appointment reflects a key milestone in the Board’s long-term succession planning process and previously disclosed CEO transition.
Scientific advances are reshaping how small cell lung cancer is understood and treated. As interest grows in first-line maintenance strategies, researchers are exploring new ways to extend the impact of initial therapy in this historically difficult-to-treat cancer. Our teams at Jazz recognize the importance of collaborating with and learning from the sleep community. Our ongoing data generation is fueled by insights from people living with narcolepsy and idiopathic hypersomnia and expand our understanding of the realities of people living with these conditions. We are focused on advancing innovation where it matters most for people facing some of the toughest cancers. Explore how our commitment to high-unmet need diseases like extensive-stage small cell lung cancer (ES-SCLC) is helping to drive meaningful progress in cancer care.